Alpa Laboratories Ltd
NSE: ALPA BSE: 532878
₹61.70
(-1.25%)
Sat, 14 Mar 2026, 11:57 pm
Market Cap1.32B
PE Ratio11.13
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KAlpa Laboratories Analysis
dividend
- Unable to evaluate Alpa Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Alpa Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Alpa Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Alpa Laboratories is profitable, therefore cash runway is not a concern.
- Alpa Laboratories is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 310.1x debt.
- Alpa Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (24.8% vs 0.3% today).
- Alpa Laboratories earns more interest than it pays, coverage of interest payments is not a concern.
- Alpa Laboratories's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
- Low level of unsold assets.
- Operating cash flow is negative therefore debt is not well covered.
management
- The tenure for the Alpa Laboratories board of directors is about average.
- Paresh's compensation has been consistent with company performance over the past year, both up more than 20%.
- Paresh's remuneration is higher than average for companies of similar size in India.
misc
- Alpa Laboratories is not covered by any analysts.
- Alpa Laboratories has significant price volatility in the past 3 months.
past
- Alpa Laboratories's year on year earnings growth rate has been positive over the past 5 years.
- Alpa Laboratories's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- It is difficult to establish if Alpa Laboratories has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- Alpa Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Alpa Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Alpa Laboratories's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Alpa Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
- ALPA outperformed the Market in India which returned -14.5% over the past year.
- NSEI:ALPA is up 17.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:ALPA is up 17.9% outperforming the market in India which returned 8% over the past month.
- Alpa Laboratories is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Alpa Laboratories is overvalued based on earnings compared to the India market.
- ALPA underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800